Endocrinology and Metabolic Disorders

The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. Rybelsus is an oral glucagon-like peptide (GLP-1) receptor protein treatment which has been approved after 15 years of the approval first GLP-1 agonist. GLP-1 is a hormone found in insufficient levels in bodies of type 2 diabetes patients. GLP-1 drugs are non-insulin treatments which, until now were administered via injection under the skin. Despite their effectiveness in lowering blood sugar level, many patients did not opt for them because of the tough and somewhat painful administration method. The approval is based on the successfu...